Tirzepatide Half-Life & Stability
Part of the full Tirzepatide guide - a unimolecular dual gip and glp-1 receptor agonist reference compound, identity-verified with a COA on every vial.
In brief
The entry supplies one explicit persistence mechanism for tirzepatide - reversible albumin binding driven by the C20 fatty-diacid side chain - and one explicit degradation-resistance mechanism - Aib substitutions at positions 2 and 13 conferring DPP-IV resistance. Beyond these two structurally grounded points, the entry provides no numeric tirzepatide-specific half-life, clearance, or stability constants, so the discussion below separates what the molecule's structure directly supports from general peptide-class storage principles, and labels the general material as such.
The detail
A closer look
01
What the structure directly supports about persistence
Two engineered features in the data bear directly on the molecule's lifetime in solution and in plasma-containing systems. First, the Aib substitutions at positions 2 and 13 confer resistance to dipeptidyl-peptidase-IV cleavage; DPP-IV is the protease that rapidly truncates native incretins at the N-terminus, so this substitution removes a major degradation route and is described in the entry as extending the intact molecule's persistence against that enzyme. Second, the C20 fatty-diacid side chain drives reversible albumin binding that extends plasma residence - a lipidation-based depot effect in which a large fraction of peptide is transiently sequestered on serum albumin and released slowly, lengthening effective lifetime. These are the only persistence mechanisms the source set asserts, and both are structure-derived rather than numeric. The entry gives no specific elimination half-life value.
02
General peptide-class stability and storage implications
Where tirzepatide-specific stability data are absent, conservative peptide-class principles apply and are flagged here as general. Lyophilized peptide is the most stable storage form and is kept cold and dry; reconstituted peptide in aqueous solution is more labile and benefits from cold storage, single-use aliquoting, and minimization of freeze-thaw cycles. Because the acylated side chain promotes albumin association, behavior in serum- or albumin-containing assay media will differ from behavior in defined buffer, with free-peptide concentration effectively buffered by albumin. None of these are tirzepatide-measured constants - they are standard lyophilized-peptide handling defaults that should be used in place of, not represented as, peptide-specific stability figures the entry does not provide.
The fine print: products are sold for laboratory research use only and are not for human or animal consumption. Bodily introduction into humans or animals is strictly prohibited by law. Tirzepatide is not a drug and is not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the FDA.